Agenda
Friday, November 10, 2017
| 7:00 AM – 8:00 AM | Registration – Arizona II & III Foyer Industry Breakfast Symposium – Arizona II & III |
PROST8™ FOR PRIMARY CARE – Moderator – David Crawford, MD
| 8:00 – 8:10 AM | Welcome and Introduction E. David Crawford, MD |
| 8:10 – 8:30 AM | Prostate Physiology: The Most Diseased Organ in the Male Body View Presentation Ryan P. Terlecki, MD, FACS |
| 8:30 – 8:50 AM | How to Differentiate the Causes of Lower Urinary Tract Symptoms View Presentation Matt T. Rosenberg, MD |
| 8:50 – 9:10 AM | Association of BPH with OAB View Presentation Ryan P. Terlecki, MD, FACS |
| 9:10 – 9:30 AM | Prostate Cancer: Why The Controversy? View Presentation Michael S Cookson, MD, MMHC |
| 9:30 – 9:50 AM | Break and Visit Exhibits – Maricopa II & III |
| 9:50 – 10:10 AM | Biomarkers: A Way Forward with Prostate Cancer Early Detection View Presentation E. David Crawford, MD |
| 10:10 – 10:30 AM | Prostate Cancer: Identifying the Toothless Lions View Presentation E. David Crawford, MD |
| 10:30 – 10:50 AM | Testosterone, the FDA, and CVD Risk Controversies View Presentation Matt T. Rosenberg, MD |
| 10:50 – 11:10 AM | The Role of Shared Decision-making in Prostate Care View Presentation Matt T. Rosenberg, MD |
| 11:10 – 11:45 AM | Panel Discussion |
| 12:00 – 1:00 PM | Industry Lunch Symposium – Maricopa I Elevate Care in Advanced Prostate Cancer Jonathan L. Silberstein, MD Supported by Astellas Pharma US and Pfizer Oncology |
26th PERSPECTIVES IN UROLOGY: POINT COUNTERPOINT
SESSION I: GENERAL UROLOGY – Manoj Monga, MD – Moderator
| 1:10 – 1:30 PM | ED and the Detection of Subclinical CVD View Presentation Ryan P. Terlecki, MD, FACS |
| 1:30 – 1:50 PM | Testosterone Therapy Update TBD |
| 1:50 – 2:10 PM | PCNL: Tips and Tricks View Presentation Manoj Monga, MD |
| 2:10– 2:40 PM | Point-Counterpoint: TRT Is Safe and Effective Pro: E. David Crawford, MD Testosterone and the Prostate View PresentationCon: Ryan P. Terlecki, MD, FACS Testosterone Safe and Effective? You Better Think Twice View Presentation |
| 2:40– 3:00 PM | Sexual and Urinary Health After Treatment for Prostate Cancer View Presentation Ryan P. Terlecki, MD, FACS |
| 3:00 – 3:20 PM | Dietary and Medical Approaches to Kidney Stone Prevention View Presentation Manoj Monga, MD |
| 3:20 – 3:45 PM | Panel Discussion |
| 3:45 – 4:00 PM | Break and Visit Exhibits – Maricopa II & III |
SESSION II: BLADDER CANCER – Michael S Cookson, MD, MMHC – Moderator
| 4:00 – 4:20 PM | BCG Failure: Defining and Managing Difficult Patients View Presentation Michael S. Cookson, MD, MMHC |
| 4:20 – 4:40 PM | Difficult Issues in Non-Muscle Invasive Bladder Cancer: Guidelines and Beyond View Presentation Michael S. Cookson, MD, MMHC |
| 4:40 – 5:00 PM | Point Counterpoint: BCG Maintenance – Full SWOG Course
Pro: Erik P. Castle, MD Con:Michael S. Cookson, MD, MMHC |
| 5:00 – 5:20 PM | Perioperative Management of the Radical Cystectomy Patient. View Presentation Erik P. Castle, MD |
| 5:20 – 5:40 PM | Immunotherapy for Metastatic Disease View Presentation Alan H. Bryce, MD |
| 5:40 – 6:00 PM | Muscle Invasive Bladder Cancer: 2017 Guidelines View Presentation Michael S. Cookson, MD, MMHC |
| 6:00 – 6:30 PM | Point-Counterpoint: The DECIPHER™ Marker Can Predict Chemotherapy Pro: Alan H. Bryce, MD View PresentationCon: Robert Abouassaly, MD View Presentation |
| 6:30 – 7:30 PM | Welcome Reception in Exhibit Hall – Maricopa II & III Supported by Bayer HealthCare |
| Evening | On Own |
Saturday, November 11, 2017
| 7:00 – 8:00 AM | Industry Breakfast Symposium – Maricopa I Risk Stratification and Molecular Markers E. David Crawford, MD Supported by KOL Consortium LLC |
SESSION III: GENITOURINARY CANCERS
E. David Crawford, MD – Moderator
| 8:00 – 8:30 AM | Germline and Somatic DNA Repair Defects in Prostate Cancer View Presentation Alan H. Bryce, MD |
| 8:30 – 9:00 AM | Therapeutic Use of Genetic Testing in Advanced Prostate Cancer View Presentation Alan H. Bryce |
| 9:00 – 9:30 AM | Recent Advances for Renal Cell Carcinoma View Presentation Erik P. Castle, MD |
| 9:30 – 10:00 AM | Point-Counterpoint: Genetic Testing Should Be Very Selectively Used in Men Pro: TBD Con: Alan H. Bryce, MD |
| 10:00 – 10:20 AM | Break and Visit Exhibits – Maricopa II & III |
| 10:20 – 10:50 AM | Upper Track Cancers View Presentation Robert Abouassaly, MD |
| 10:50– 11:10 AM | Adjuvant Sunitinib for High Risk RCC View Presentation Alan H. Bryce, MD |
| 11:00 – 11:30 AM | Cancer Survivorship View Presentation Ryan P. Terlecki, MD, FACS |
| 11:00 – 12:15 PM | GU Tumor Board Case Panel Moderated by Robert E. Donohue, MD |
| 12:15 PM – 1:30 PM | Resident’s Bowl Moderated by Erik P. Castle, MD |
| Afternoon and Evening | On Own |
Sunday, November 12, 2017
| 7:00 – 8:00 AM | Industry Breakfast Symposium – Maricopa II & III |
SESSION IV: LOCALIZED PROSTATE CANCER –
Andrew J. Stephenson, MD, FACS, FRCSC – Moderator
| 8:00 – 8:20 AM | Updates in Radiation Oncology: Of Brachytherapy and Beams? View Presentation David C. Beyer, MD |
| 8:20 – 8:40 AM | MRI-Guided Biopsies View Presentation Robert Abouassaly, MD |
| 8:40 – 9:00 AM | MRI in the Management of Prostate Cancer: What the Urologist Needs to Know View Presentation Michael S. Cookson, MD, MMHC |
| 9:00 – 9:30 AM | Panel Discussion |
| 9:30 – 9:50 AM | Break and Visit Exhibits – Maricopa II & III |
| 9:50 – 10:20 AM | Point-Counterpoint: HiFU: Ready for Prime Time?
Pro: David C. Beyer, MD
|
| 10:20 – 10:40 AM | Imaging of Prostate Cancer Patients Following Definitive Therapy View Presentation Phillip J. Koo, MD |
| 10:40 – 11:00 AM | Bladder Neck Contractures After Prostatectomy View Presentation Ryan P. Terlecki, MD, FACS |
| 11:00 – 11:30 AM | Panel Discussion |
| 11:30 – 12:30 PM | Lunch Break |
SESSION V: ADVANCED PROSTATE CANCER – E. David Crawford, MD – Moderator
| 12:30 – 12:50 PM | Castrate Resistant Prostate Cancer: Update on Therapy and Sequencing Michael S. Cookson, MD, MMHC |
| 12:50 – 1:10 PM | Novel Hormonal Therapies for Prostate Cancer View Presentation Alan H. Bryce, MD |
| 1:10 – 1:30 PM | Therapeutic Radiopharmaceuticals and the Emergence of Theranostics View Presentation Phillip J. Koo, MD |
| 1:30 – 1:50 PM | Immunotherapy for CRPC View Presentation E. David Crawford, MD |
| 1:50 – 2:10 PM | Timing and Optimization of Radium 223 in CRPC View Presentation Phillip J. Koo, MD |
| 2:10 – 3:00 PM | Panel Discussion |
| 3:00 PM | Closing Remarks E. David Crawford, MD |